JP2016538307A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538307A5 JP2016538307A5 JP2016534953A JP2016534953A JP2016538307A5 JP 2016538307 A5 JP2016538307 A5 JP 2016538307A5 JP 2016534953 A JP2016534953 A JP 2016534953A JP 2016534953 A JP2016534953 A JP 2016534953A JP 2016538307 A5 JP2016538307 A5 JP 2016538307A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- lung cancer
- small cell
- cell lung
- carbon atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 14
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 239000007962 solid dispersion Substances 0.000 claims 5
- -1 methyl ( S)-{4- (3′-cyanobiphenyl-4-yl) -2,3,9-trimethyl-6H-thieno [3,2-f] [1,2,4] triazolo [4,3-a ] [1,4] diazepin-6-yl} acetate Chemical compound 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 230000003828 downregulation Effects 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 3
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims 2
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 2
- 108091005625 BRD4 Proteins 0.000 claims 2
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims 2
- 102000006311 Cyclin D1 Human genes 0.000 claims 2
- 108010058546 Cyclin D1 Proteins 0.000 claims 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 2
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 claims 2
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 claims 2
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 claims 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 2
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 claims 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims 2
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 claims 2
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- 230000003827 upregulation Effects 0.000 claims 2
- YBPAYPRLUDCSEY-UHFFFAOYSA-N 2-(4-hydroxyphenyl)acetamide Chemical compound NC(=O)CC1=CC=C(O)C=C1 YBPAYPRLUDCSEY-UHFFFAOYSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 108050004367 HEXIM Proteins 0.000 claims 1
- 102000016053 HEXIM Human genes 0.000 claims 1
- 101150105104 Kras gene Proteins 0.000 claims 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 1
- 101150022024 MYCN gene Proteins 0.000 claims 1
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 claims 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical group O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 1
- 229960005061 crizotinib Drugs 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 150000004683 dihydrates Chemical class 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361909599P | 2013-11-27 | 2013-11-27 | |
| US61/909,599 | 2013-11-27 | ||
| US201462012042P | 2014-06-13 | 2014-06-13 | |
| US62/012,042 | 2014-06-13 | ||
| US201462080779P | 2014-11-17 | 2014-11-17 | |
| US62/080,779 | 2014-11-17 | ||
| PCT/EP2014/075707 WO2015078928A1 (en) | 2013-11-27 | 2014-11-26 | Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016538307A JP2016538307A (ja) | 2016-12-08 |
| JP2016538307A5 true JP2016538307A5 (enExample) | 2018-01-11 |
Family
ID=52021167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534953A Pending JP2016538307A (ja) | 2013-11-27 | 2014-11-26 | チエノトリアゾロジアゼピン化合物を含む医薬製剤を使用する非小細胞肺癌の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9820992B2 (enExample) |
| EP (1) | EP3074019A1 (enExample) |
| JP (1) | JP2016538307A (enExample) |
| KR (1) | KR20160079822A (enExample) |
| CN (1) | CN105813643A (enExample) |
| WO (1) | WO2015078928A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3137086A4 (en) * | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
| JP2017517579A (ja) * | 2014-06-13 | 2017-06-29 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる非小細胞肺癌及び／又は小細胞肺癌の治療方法 |
| KR102592845B1 (ko) | 2017-05-31 | 2023-10-20 | 아유미 세이야쿠 가부시키가이샤 | 6H-티에노[2,3-e][1,2,4]트리아졸로[3,4-c][1,2,4]트리아제핀 유도체 |
| KR20240028420A (ko) | 2021-06-08 | 2024-03-05 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항암 화합물 |
| US12527741B2 (en) | 2021-06-17 | 2026-01-20 | Wisconsin Alumni Research Foundation | Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2412776C (en) * | 2000-06-16 | 2011-03-15 | Mitsubishi Pharma Corporation | Compositions controlling release ph range and/or speed |
| US8476260B2 (en) * | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| MX384074B (es) | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| WO2012068339A2 (en) * | 2010-11-17 | 2012-05-24 | Glaxosmithkline Llc | Methods of treating cancer |
| DE102011082013A1 (de) * | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| US9700619B2 (en) | 2011-11-11 | 2017-07-11 | Duke University | Combination drug therapy for the treatment of solid tumors |
| WO2013074518A1 (en) * | 2011-11-14 | 2013-05-23 | Tesaro, Inc. | Modulating certain tyrosine kinases |
| EP2620140A1 (en) | 2012-01-26 | 2013-07-31 | ratiopharm GmbH | Crizotinib containing compositions |
| CN103305625B (zh) * | 2013-07-08 | 2014-06-25 | 广东省人民医院 | 检测非小细胞肺癌驱动基因突变谱的方法及试剂盒与应用 |
-
2014
- 2014-11-26 JP JP2016534953A patent/JP2016538307A/ja active Pending
- 2014-11-26 US US15/039,442 patent/US9820992B2/en not_active Expired - Fee Related
- 2014-11-26 WO PCT/EP2014/075707 patent/WO2015078928A1/en not_active Ceased
- 2014-11-26 KR KR1020167013579A patent/KR20160079822A/ko not_active Withdrawn
- 2014-11-26 CN CN201480065214.5A patent/CN105813643A/zh active Pending
- 2014-11-26 EP EP14809782.7A patent/EP3074019A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529246A5 (enExample) | ||
| JP2017517579A5 (enExample) | ||
| JP2017519727A5 (enExample) | ||
| JP2011515397A5 (enExample) | ||
| RU2016147946A (ru) | Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений | |
| JP2013510123A5 (enExample) | ||
| RU2017100921A (ru) | Способ лечения немелкоклеточного рака легких и/или мелкоклеточного рака легких с применением соединений тиенотриазолодиазепина | |
| JP6289459B2 (ja) | ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法 | |
| JP2016040288A5 (enExample) | ||
| JP2019512535A5 (enExample) | ||
| JP2016525563A5 (enExample) | ||
| RU2015101106A (ru) | Способ лечения лимфомы, применяя тиенотриазолодиазепиновые соединения | |
| JP2015511638A5 (enExample) | ||
| JP2016538310A5 (enExample) | ||
| RU2016146102A (ru) | Способ лечения резистентной неходжкинской лимфомы, медуллобластомы и/или alk+ немелкоклеточного рака легкого с применением тиенотриазолодиазепиновых соединений | |
| JP2017533249A5 (enExample) | ||
| JP2012136540A5 (enExample) | ||
| JP2017502014A5 (enExample) | ||
| JP2016513137A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| JP2016517404A5 (enExample) | ||
| RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
| JP2012526148A5 (enExample) | ||
| CY1123346T1 (el) | Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα |